Arcturus Therapeutics (ARCT) Q2 FY26 earnings call

Arcturus Therapeutics reported continued execution across its rare disease pipeline and significant strategic developments for its vaccine franchise in Q2 FY26. The company regained global rights to its self-amplifying mRNA platform and vaccine portfolio, positioning it for future commercialization and partnering opportunities. Clinical programs for Cystic Fibrosis and OTC deficiency advanced, with key data readouts and regulatory decisions anticipated in the coming quarters, supported by a robust cash runway.